PTC Therapeutics | PTCT - Cost Of Sales

Stock Price
64.06
Daily Change
-6.20 -8.82%
Monthly
-2.41%
Yearly
29.36%
Q2 Forecast
66.77

PTC Therapeutics reported $16.3M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
TG Therapeutics USD 38.14M 10.05M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025